San Francisco-based NewLimit, co-founded by Coinbase CEO Brian Armstrong, is focused on extending human healthspan and tackling age-related diseases, supported by a $40 million Series A financing and an initial $110 million investment.

The company has made significant advancements in epigenetic reprogramming, aiming to restore youthful functions in liver and immune cells.

By the end of 2024, NewLimit completed its first reprogramming screens in humanized livers, identifying factors that rejuvenate aged hepatocytes and enhance liver function.

NewLimit has significantly improved its humanized liver screening system's capacity by twenty-fold, enabling more extensive experimentation with transcription factor sets.

Utilizing advanced techniques such as single-cell multi-omics and machine learning, NewLimit is discovering transcription factors that restore youthful functions to aged cells.

In terms of T cell function, NewLimit identified three transcription factors that restore youthful activity in aged CD8 T cells, which are crucial for immune defense against infections and cancer.

Additionally, the company discovered ten more transcription factor sets that can make old T cells resemble young ones in terms of gene expression.

Jacob C Kimmel, head of research, emphasized that this represents a pioneering demonstration of partial reprogramming rescuing human CD8 T cell function, although clinical trials are still some years away.

Furthermore, a prototype LNP-mRNA medicine has shown promising results in enhancing liver regeneration in pre-clinical models, particularly in simulating alcohol-induced liver damage.